Zenith Drugs (NSE:ZENITHDRUG) Research & Development: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZENITHDRUG Zenith Drugs Ltd NSE:ZENITHDRUG
45 GF Score
Price ₹49.10
! 8 Warning Signs
View Full Analysis

What is Zenith Drugs Research & Development?

Zenith Drugs NSE:ZENITHDRUG -1.21% 45 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 45/100. The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Zenith Drugs's Research & Development for the six months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Zenith Drugs  (NSE:ZENITHDRUG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zenith Drugs Research & Development Related Terms

Zenith Drugs Research & Development Historical Data

* Premium members only.

The historical data trend for Zenith Drugs's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs Research & Development Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Zenith Drugs Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:ZENITHDRUG
45GF Score
Zenith Drugs Ltd NSE:ZENITHDRUG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenith Drugs Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Zenith Drugs (NSE:ZENITHDRUG) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Zenith Drugs and its competitors.
Is Zenith Drugs' Research & Development too high?
Zenith Drugs' current Research & Development is ₹0 Mil. Overall, Zenith Drugs has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Research & Development compare to ZTS and UTHR?
Zenith Drugs' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zenith Drugs and its competitors. Zenith Drugs's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. Zenith Drugs' overall GF Score™ is 45/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenith Drugs Business Description

Address K. No. 72/5, Village Muradpura, Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
45GF Score

Get the complete analysis for NSE:ZENITHDRUG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹49.10
Price